We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Biolex Presents Phase 2b Results at EASL Showing Reduced Rates of Depression in HCV Patients Treated With Locteron®

News   Apr 04, 2011

 
Biolex Presents Phase 2b Results at EASL Showing Reduced Rates of Depression in HCV Patients Treated With Locteron®
 
 
Advertisement
 

RELATED ARTICLES

Neanderthal Protein May Reduce the Severity of COVID-19

News

Researchers at the Lady Davis Institute (LDI) at the Jewish General Hospital have discovered that increased levels of the protein OAS1 are associated with reduced mortality and less severe disease requiring ventilation among patients with COVID-19. Using drugs that boost OAS1 levels could be explored to try to improve these outcomes.

READ MORE

Might COVID-19's Cytokine Storms Be Kept in Check With Vitamin B6?

News

Research suggests that vitamin B6 has the potential to lower the odds of patients becoming seriously ill with the coronavirus.

READ MORE

64 Human Genomes Sequenced as a New Reference for Genetic Variation

News

Researchers have detailed the sequencing of 64 full human genomes. This will enable studies on genetic predispositions to human diseases as well as the discovery of more complex forms of genetic variation.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE